Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.02 USD | +0.74% | +7.76% | +191.32% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 5.5M | Capitalization | 345M |
---|---|---|---|---|---|
Net income 2024 * | -67M | Net income 2025 * | -77M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 62.7 x |
P/E ratio 2024 * |
-4.92
x | P/E ratio 2025 * |
-5.82
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.39% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +5.76% | ||
1 week | +6.65% | ||
Current month | -4.29% | ||
1 month | -5.48% | ||
3 months | +20.62% | ||
6 months | +273.28% | ||
Current year | +189.54% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 22.98 | +0.61% | 47 416 |
24-05-16 | 22.84 | +5.76% | 77,712 |
24-05-15 | 21.6 | +3.25% | 101,371 |
24-05-14 | 20.92 | +0.77% | 39,212 |
24-05-13 | 20.76 | -2.67% | 35,493 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+189.54% | 345M | |
+32.36% | 694B | |
+29.95% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.53% | 239B | |
+10.20% | 209B | |
-3.19% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- JSPR Stock